Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 15;239(Pt 1):117297.
doi: 10.1016/j.envres.2023.117297. Epub 2023 Oct 8.

Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies

James Hollister  1 , Alberto J Caban-Martinez  2 , Katherine D Ellingson  3 , Shawn Beitel  3 , Ashley L Fowlkes  4 , Karen Lutrick  5 , Harmony L Tyner  6 , Allison L Naleway  7 , Sarang K Yoon  8 , Manjusha Gaglani  9 , Danielle Hunt  10 , Jennifer Meece  11 , Julie Mayo Lamberte  4 , Natasha Schaefer Solle  2 , Spencer Rose  12 , Kayan Dunnigan  12 , Sana M Khan  3 , Jennifer L Kuntz  7 , Julia M Fisher  13 , Alissa Coleman  3 , Amadea Britton  4 , Matthew S Thiese  14 , Kurt T Hegmann  14 , Marian Pavuk  15 , Ferris A Ramadan  16 , Sammantha Fuller  10 , Amy Nematollahi  3 , Ryan Sprissler  17 , Jefferey L Burgess  3
Affiliations

Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies

James Hollister et al. Environ Res. .

Abstract

Per- and polyfluoroalkyl substances (PFAS) are ubiquitous throughout the United States. Previous studies have shown PFAS exposure to be associated with a reduced immune response. However, the relationship between serum PFAS and antibody levels following SARS-CoV-2 infection or COVID-19 vaccination has not been examined. We examined differences in peak immune response and the longitudinal decline of antibodies following SARS-CoV-2 infection and COVID-19 vaccination by serum PFAS levels in a cohort of essential workers in the United States. We measured serum antibodies using an in-house semi-quantitative enzyme-linked immunosorbent assay (ELISA). Two cohorts contributed blood samples following SARS-CoV-2 infection or COVID-19 vaccination. We used linear mixed regression models, adjusting for age, race/ethnicity, gender, presence of chronic conditions, location, and occupation, to estimate differences in immune response with respect to serum PFAS levels. Our study populations included 153 unvaccinated participants that contributed 316 blood draws over a 14-month period following infection, and 860 participants and 2451 blood draws over a 12-month period following vaccination. Higher perfluorooctane sulfonic acid (PFOS), perfluorohexane sulfonic acid (PFHxS), and perfluorononanoic acid (PFNA) concentrations were associated with a lower peak antibody response after infection (p = 0.009, 0.031, 0.015). Higher PFOS, perfluorooctanoic acid (PFOA), PFHxS, and PFNA concentrations were associated with slower declines in antibodies over time after infection (p = 0.003, 0.014, 0.026, 0.025). PFOA, PFOS, PFHxS, and PFNA serum concentrations prior to vaccination were not associated with differences in peak antibody response after vaccination or with differences in decline of antibodies over time after vaccination. These results suggest that elevated PFAS may impede potential immune response to SARS-CoV-2 infection by blunting peak antibody levels following infection; the same finding was not observed for immune response to vaccination.

Keywords: COVID-19 vaccine; Immune response; PFOA; PFOS; Per- and polyfluoroalkyl substances (PFAS); SARS CoV-2 infection.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Allison L Naleway reports a relationship with Pfizer Inc that includes: funding grants. Allison L Naleway reports a relationship with Vir Biotechnology Inc that includes: funding grants. Kurt Hegmann reports a relationship with American College of Occupational and Environmental Medicine that includes: consulting or advisory. Kurt Hegmann reports a relationship with National Institute for Occupational Safety and Health that includes: funding grants. Manjusha Gaglani reports a relationship with Westat Inc that includes: funding grants. Manjusha Gaglani reports a relationship with Vanderbilt University Medical Center that includes: funding grants. Manjusha Gaglani reports a relationship with Abt Associates Inc that includes: funding grants. Manjusha Gaglani reports a relationship with Infectious Diseases and Immunization Committee, Texas Pediatric Society, Texas Chapter of the American Academy of Pediatrics that includes: board membership. Ryan Sprissler reports a relationship with American Council of Life Insurers that includes: speaking and lecture fees. Ryan Sprissler reports a relationship with California legal case Ebers v. Castle Park that includes: consulting or advisory. Ryan Sprissler reports a relationship with Geneticure, Inc. that includes: equity or stocks. Ryan Sprissler reports a relationship with Beckman Coulter that includes: speaking and lecture fees. Ryan Sprissler reports a relationship with Shay Emma Hammer Research Foundation that includes: board membership. Ryan Sprissler has patent issued to Arizona Board of Regents on Behalf of the University of Arizona.

Figures

Figure 1.
Figure 1.
Flowchart for determination of final population for post-infection analysis from the AZ-HEROES/RECOVER cohorts.
Figure 2.
Figure 2.
Flowchart for determination of final population for post-vaccination analysis from the AZ-HEROES/RECOVER cohorts.
See this image and copyright information in PMC

References

    1. Ahuja V, et al. , 2009. Ammonium perfluorooctanoate substantially alters phenotype and cytokine secretion of human monocyte-derived dendritic cells in vitro. Immunopharmacology and Immunotoxicology. 31, 641–646. - PubMed
    1. Amanat F, et al. , 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature Medicine. 26, 1033–1036. - PMC - PubMed
    1. ATSDR, PFAS in the U.S. Population. In: ATSDR, (Ed.), 2022.
    1. Bailey JM, et al. , 2023. Immune response to COVID-19 vaccination in a population with a history of elevated exposure to per- and polyfluoroalkyl substances (PFAS) through drinking water. Journal of Exposure Science & Environmental Epidemiology. - PMC - PubMed
    1. Bogdanska J, et al. , 2020. Tissue distribution of (14)C-labelled perfluorooctanoic acid in adult mice after 1–5 days of dietary exposure to an experimental dose or a lower dose that resulted in blood levels similar to those detected in exposed humans. Chemosphere. 239, 124755. - PubMed

Publication types